{"product_id":"tunlametinib","title":"Tunlametinib","description":"\u003cp\u003eTunlametinib (HL-085)  is an oral, selective, mitogen-activated protein kinase kinase 1 and 2 (MEK 1\/2) inhibitor, for the treatment of solid tumours with RAS and RAF mutations, including melanoma, non-small cell cancer (NSCLC), colorectal cancer (CRC) and neurofibromatosis type 1 (NF1) plexiform neurofibromas. \u003c\/p\u003e\u003cul\u003e\u003cli\u003eTunlametinib sold under the brand name 科露平\u003csup\u003e®\u003c\/sup\u003e in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eMarch 18, 2024, China’s National Medical Products Administration (NMPA) has approved tunlametinib (HL-085) for the treatment of patients with advanced melanoma harboring \u003cem\u003eNRAS\u003c\/em\u003e mutations who were previously treated with anti–PD-1\/PD-L1 therapy.\u003c\/p\u003e","brand":"Shanghai KeChow Pharma, Inc., China","offers":[{"title":"Default Title","offer_id":44797957308459,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-2027.png?v=1787022281","url":"https:\/\/xomeds.com\/products\/tunlametinib","provider":"XOMEDS","version":"1.0","type":"link"}